If you add up the risk-adjusted net present values of both indications, including a 0.3 rest-of-world multiple, with its cash ...

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ...

Intravitreal brolucizumab is superior to panretinal laser photocoagulation in preserving visual acuity for patients with proliferative diabetic retinopathy, clinical trial data show.

Ocular infections and related inflammatory disorders are important causes of visual morbidity worldwide and may arise from viral, bacterial, fungal, and ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% ...

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever ...

Ocular surface cooling devices for chronic ocular surface pain are safe and provide durable symptom relief at 1 year, according to ASCRS 2026 data.

Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies ...

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.